Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026
CytomX Therapeutics, Inc. (CTMX)
A forensic read on CytomX Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-10.1
Distress distance
Watch
Earnings quality
4
Forensic signals
-35.2%
ROE
-44.8%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
CytomX Therapeutics, Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -10.1, placing it in the Distress zone. 4 forensic signals were flagged in its latest SEC filings, led by cash conversion.
What the filings flag
-15.64×
FY2023–FY2025
Cash conversion.Over FY2023–FY2025, cumulative operating cash flow was -15.64× cumulative net income. Reported profit is not turning into cash. The shortfall is profit tied up in working capital rather than collected — the accrual and receivables lines below show where.Cash conversion: operating cash flow divided by net income, the share of profit that arrived as cash.
+36.7%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +87% over the last 2 years to FY2025 (+36.7%/yr). The count is growing — 73.8M shares in FY2023, 137.9M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~36.7% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~46%.
8% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 8% of revenue in FY2025 — about $0.05 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 36.7% a year across FY2023–FY2025 and that rate is not falling, so total profit has to grow by that much annually before any of it reaches a share. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
n/m (sign flip)
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets flipped from negative to positive FY2024→FY2025 (FY2024 $-38.5M to FY2025 $+86.3M) — the standard accruals ratio divides by the average of the two, which collapses toward zero right as the sign changes, so the resulting percentage is a denominator artifact, not a real accrual measurement. Treat this as a structural balance-sheet shift to understand on its own terms rather than a clean or dirty accruals read.Accruals ratio: the year-over-year change in net operating assets, relative to their own average.NOA (net operating assets): the money tied up in running the business, operating assets minus operating liabilities.
Key fundamentals
Latest Revenue$76.2M
Revenue Growth YoY-44.8%
Revenue CAGR (2yr)-13.2%
Net Margin-22.8%
Free Cash Flow-$75.8M
Return on Equity-35.2%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from CytomX Therapeutics, Inc.'s actual 10-K/10-Q/8-K filings?